$52.70
3.95% today
Nasdaq, Apr 04, 09:18 pm CET
ISIN
US09073M1045
Symbol
TECH
Sector
Industry

Bio-Techne Corporation Stock price

$54.86
-6.33 10.34% 1M
-19.14 25.86% 6M
-17.17 23.84% YTD
-13.01 19.17% 1Y
-53.15 49.21% 3Y
+8.26 17.73% 5Y
+30.23 122.74% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-3.52 6.03%
ISIN
US09073M1045
Symbol
TECH
Sector
Industry

Key metrics

Market capitalization $8.67b
Enterprise Value $8.89b
P/E (TTM) P/E ratio 55.76
EV/FCF (TTM) EV/FCF 34.96
EV/Sales (TTM) EV/Sales 7.43
P/S ratio (TTM) P/S ratio 7.25
P/B ratio (TTM) P/B ratio 4.17
Dividend yield 0.58%
Last dividend (FY24) $0.32
Revenue growth (TTM) Revenue growth 4.46%
Revenue (TTM) Revenue $1.20b
EBIT (operating result TTM) EBIT $256.21m
Free Cash Flow (TTM) Free Cash Flow $254.30m
Cash position $177.55m
EPS (TTM) EPS $0.98
P/E forward 48.72
P/S forward 7.05
EV/Sales forward 7.23
Short interest 4.55%
Show more

Is Bio-Techne Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Bio-Techne Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Bio-Techne Corporation forecast:

12x Buy
67%
6x Hold
33%

Analyst Opinions

18 Analysts have issued a Bio-Techne Corporation forecast:

Buy
67%
Hold
33%

Financial data from Bio-Techne Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,196 1,196
4% 4%
100%
- Direct Costs 401 401
7% 7%
34%
795 795
3% 3%
66%
- Selling and Administrative Expenses 329 329
7% 7%
28%
- Research and Development Expense 99 99
6% 6%
8%
367 367
1% 1%
31%
- Depreciation and Amortization 111 111
0% 0%
9%
EBIT (Operating Income) EBIT 256 256
1% 1%
21%
Net Profit 158 158
29% 29%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Bio-Techne Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bio-Techne Corporation Stock News

Neutral
PRNewsWire
2 days ago
MINNEAPOLIS , April 2, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD), and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automation of ACD's new RNAscope™ Multiomic LS Assay and ...
Neutral
PRNewsWire
9 days ago
MINNEAPOLIS , March 26, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will open a new Customer Experience Centre in Düsseldorf, Germany to serve customers across the Europe, Middle East and Africa (EMEA) region and support the company's long-term regional growth strategy. The new Customer Experience Centre is scheduled to open in summer 2026 and will feature a st...
Neutral
PRNewsWire
11 days ago
MINNEAPOLIS , March 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced further advancements in its ongoing strategy to bring translational discoveries to patient care by leveraging RNAscope technology to address unmet needs in biomarker detection and improve pathology laboratory workflows. These advancements will be highlighted in a seminar at the United States and C...
More Bio-Techne Corporation News

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Biotechnology, Protein Platforms, Diagnostics, and Corporate. The Biotechnology segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and related reagents, as well as in situ hybridization, media and other cell culture products and reagents to the biotechnology research community. The Protein Platforms segment develops, manufactures, and sells tools to simplify protein analysis. The Diagnostics segment includes blood chemistry and blood gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market worldwide. The company was founded on 1976 and is headquartered in Minneapolis, MN.

Head office United States
CEO Kim Kelderman
Employees 3,100
Founded 1976
Website www.bio-techne.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today